Today, specialists from the research department of the World Health Organization have compiled a new report on the number of people who die each year from malaria in one form or another – and this number was about 429 thousand people. In order to minimize such a harmful effect of malaria, microbiology specialists from the University of California decided to contribute to this struggle by presenting a prototype of a new medicine based on a unique neurotoxin that affects only insect vectors of malaria – in particular, the Anopheles mosquitoes, which are the most common carriers.
Malaria is transmitted through these mosquitoes, which in turn receive infection through plasmodium parasites – and despite the fact that the plasmodian bacterium itself kills mosquitoes, the very method of drug development using such a mechanism has long escaped experts. However, today a team of researchers submitted a report according to which they managed to create such a prototype drug based on a neurotoxin called PMP1 – it was found as a result of comparing the protein map of the lethal version of the antimalarial bacterium and non-lethal strain.
They also noticed that malaria somehow changes depending on the region, and also depending on what kind of mosquito family it carries. In any case, experts continue to experiment with the non-lethal version of their preliminary serum, continually mixing it with other strains of bacteria and identifying the most ideal balance between efficacy and safety.
This is necessary in order to effectively destroy mosquitoes and the infection transmitted by them at the same time, but at the same time not cause great damage to the potential patient's immune system – because malaria in itself depletes the body no worse than any other protracted illness. So it remains to wait for the final result of a new study and a new serum against malaria.